Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00323102 · ClinicalTrials.gov registry record · Phase 4
A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain
A Phase 4 study of Brain Pathology, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- Phase 4
- Development phase
- 114
- Enrollment target
- 1
- Study location
NCT00323102 is a Phase 4 study of Brain Pathology that has completed, run by Bracco Diagnostics. The registered enrollment target is 114 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00323102, a Phase 4 study of Brain Pathology, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 114 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims at a direct comparison between Multihance and a validated comparator like Omniscan in a cross-over individual design in patients with brain tumors to confirm the superior overall diagnostic performance of MuliHance for this indication
Conditions Studied
Interventions
- DRUG Multihance
Study Locations (1)
New Jersey
- Bracco Diagnostics, Inc. - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00323102
The ClinicalTrials.gov registry entry for NCT00323102 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Pathology appearing as the primary indexed condition, and to 1 intervention - of which Multihance is the first listed.
NCT00323102 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00323102 about?
NCT00323102 is a clinical study titled "A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain". This study aims at a direct comparison between Multihance and a validated comparator like Omniscan in a cross-over individual design in patients with brain tumors to confirm the superior overall diagnostic performance of MuliHance for this indication
What is the current status of trial NCT00323102?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 114 participants. The study started on 2006-05. Estimated completion is 2007-03.
What conditions does trial NCT00323102 study?
This clinical trial studies the following conditions: Brain Pathology.
What interventions are being tested in trial NCT00323102?
The interventions under investigation include: Multihance (DRUG).
Who is sponsoring clinical trial NCT00323102?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00323102 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.